Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $8.39 Consensus Price Target from Analysts

Revance Therapeutics, Inc. (NASDAQ:RVNC) has received an average recommendation of “Hold” from the nine analysts that are covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $8.39.

Several brokerages recently commented on RVNC. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. StockNews.com assumed coverage on Revance Therapeutics in a research note on Saturday. They issued a “hold” rating on the stock. Barclays reduced their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd. Mizuho dropped their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research report on Tuesday, December 10th. Finally, HC Wainwright restated a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a report on Friday, November 8th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alpine Global Management LLC bought a new position in Revance Therapeutics in the fourth quarter worth approximately $37,000. Two Sigma Investments LP lifted its holdings in shares of Revance Therapeutics by 8.6% in the fourth quarter. Two Sigma Investments LP now owns 170,136 shares of the biopharmaceutical company’s stock valued at $517,000 after purchasing an additional 13,539 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of Revance Therapeutics by 19.3% in the fourth quarter. ProShare Advisors LLC now owns 75,252 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 12,155 shares in the last quarter. Man Group plc lifted its holdings in shares of Revance Therapeutics by 47.8% in the fourth quarter. Man Group plc now owns 443,544 shares of the biopharmaceutical company’s stock valued at $1,348,000 after purchasing an additional 143,544 shares in the last quarter. Finally, Newtyn Management LLC bought a new position in shares of Revance Therapeutics in the fourth quarter valued at approximately $5,502,000. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Stock Performance

Shares of RVNC opened at $3.65 on Thursday. The firm’s fifty day simple moving average is $3.42 and its two-hundred day simple moving average is $4.57. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $7.56. The stock has a market capitalization of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.